Fulvestrant

Updated 
January 26, 2018
Reviewed By: 

Fulvestrantinfo-icon (Faslodexinfo-icon) is an estrogen receptorinfo-icon antagonistinfo-icon, or ERA, a class of medicineinfo-icon that stops the activity of estrogeninfo-icon on cancer cells to keep them from growing.

Who Gets Fulvestrant

Fulvestrantinfo-icon is FDAinfo-icon approved for use in postmenopausalinfo-icon women with metastaticinfo-icon hormone receptorinfo-icon-positive breast cancer. It may be given

  • to postmenopausal women, if the cancer is HER2-negative and they have not received hormonal therapyinfo-icon
  • to postmenopausal women, if the cancer grew while taking a different hormonal therapy
  • to anyone, with palbociclib (Ibrance) or abemaciclib (Verzenio) whose cancer grew despite treatment with a different hormonal therapy for early or metastatic breast cancer

How Fulvestrant Is Given

Fulvestrantinfo-icon is given by injectioninfo-icon into the buttocks. For the first month, you will receive two shots every 2 weeks. Afterward, it is given as two injections every 4 weeks.

Side Effects and Things to Remember

Common side effects of fulvestrant are:

You should not take fulvestrant if you are pregnant, and you should not become pregnant while taking it or for a year after treatment ends as fulvestrant can harm the fetus. You also should not breastfeed while taking fulvestrant.

More In Hormonal Therapy